OPEN

3D Printed Polyvinyl Alcohol Tablets with Multiple Release Profiles

Xiaowen Xu¹, Jingzhou Zhao¹, Maonan Wang¹, Liang Wang^{2,3} & Junliang Yang¹

The aim of this study was to explore the feasibility of using different 3D printed internal geometries as tablet formulations to obtain controlled release profiles. In order to obtain controllable release profiles, three types of tablet models (Cylinder, Horn and Reversed Horn) with controlled structures were designed. The cylinder model shows a constant release profile and can keep the drug concentration within a certain range. The horn model exhibits an increasing release profile, which is suitable for the patients who have the drug resistance in the course of medication. The reversed horn model has a decreasing release profile that would be applied to hypertension cure. Furthermore, three types of tablets were fabricated successfully by a fused deposition modeling three-dimensional (3D) printer and injected with paracetamol (APAP) -containing gels. The results of *in vitro* drug release demonstrate that tablets with three kinds of structures can produce constant, gradually increasing, and gradually decreasing release profiles, respectively. The release attributes can be controlled by using different 3D printed geometries as tablet formulations. More importantly, there are no residues after dissolution. The method of preparing customized tablets with distinguished release profiles presented in this study has the promising potential in the fabrication of patient-tailored medicines.

Three-dimensional (3D) printing or additive manufacturing is a rapid prototyping technology that prints 3D objects by layer-by-layer deposition approach controlled by computer-aided design software¹. 3D printing has been used to generate complex structures, which are very challenge to manufacture with traditional techniques. It has been studied in the medical and pharmaceutical applications such as tissue engineering^{2–5}, dentistry⁶, and implants^{7,8}. Tablets with different structures and materials will have distinguished release profiles⁹. In August 2015, the application of 3D printing in the pharmaceutical industry was approved by US Food and Drug Administration (FDA)^{9,10}, indicating that 3D printing could elaborate its advantages in personalized medicine.

Recently many researchers have paid more efforts to employ 3D printing to develop personalized medicines^{11–13} and drug delivery system^{14–21}. There are multiple 3D printing technologies utilized in customized medicines, such as Stereolithography (SLA)²², Selective Laser Sintering (SLS)^{23,24}, Fused Deposition Modelling (FDM)^{13,25,26}, Semi-solid extrusion (SSE)²⁷ and Powder Based (PB)²⁸. 3D printing is used to fabricate oral dosage forms and demonstrates great potentials in the pharmaceutical industry^{12,13,29,30}. Currently, researchers fabricated controlled-release drugs with different characteristics by 3D printing^{22,30–36}. Tablets with different structures and materials will have distinguished release profiles⁹. Yu *et al.* employed PB 3D printing to develop doughnut-shaped multi-layered tablets with linear release profile²⁸. Wang *et al.* used SLA 3D printer to manufacture drug-loaded tablets with modified-release characteristics and revealed that the release profile of the drugs was dependent on the composition of the formulations²². Trenfield *et al.* fabricated printlets with three different geometries using a desktop SLS printer and developed a calibration model to predict drug concentration of a different geometry^{37,38}. Of these 3DP technologies FDM technology exhibits the excellent promise in fabricating drug products, because FDM printers are low-cost, easy to operate⁹ and able to refine hollow objects³⁹. FDM 3D printing has recently attracted increasing interests as one of the most widely used techniques for developing individualized medicines in pharmaceutical applications¹³. Muwaffak *et al.* used 3D scanning to construct models of a nose and ear and printed a customized wound dressing using antimicrobial metals incorporated into polycaprolactone (PCL) to produce filaments for 3D printing⁴⁰. These metals

¹School of Physics and Electronics, Central South University, Changsha, Hunan, 410083, China. ²Department of Bioinformatics, School of Medical Informatics and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China. ³Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China. Correspondence and requests for materials should be addressed to J.Y. (email: junliang.yang@csu.edu.cn)

with broad-spectrum antimicrobial properties can improve the wound healing process^{41,42}. FDM 3D printing is an effective process to fabricate tablets with modified release profiles. FDM printer has been used to produce immediate, sustained, and time-released tablets⁴³. It is able to manufacture complex shapes and geometries to obtain different release profiles in personalized medicine^{9,44}. Skowrya *et al.* used FDM printer to produce prednisolone sustained-release tablets¹³. Melocchi *et al.* explored the potential of FDM 3D printing to manufacture oral capsular devices for pulsatile release²⁵. Chai *et al.* explored the potential of FDM 3D printing to prepare sustained-release drugs, which could be released in the stomach for a long time⁴⁵. Goyanes *et al.* produced tablets with different geometrical shapes by FDM 3D printing and demonstrated that tablet shape could affect drug release profile⁴⁴.

Hydroxypropyl methylcellulose (HPMC), a non-toxic and safe pharmaceutical excipient, has been employed as the forming agents and binding additives in order to obtain sustained release^{33,46–49}. Zhang *et al.* explored the relationship between drug release and the geometrical shape of the 3D printed tablets with different structures printed by FDM printing⁵⁰. The desktop 3D printer was used to produce bilayer tablets with a definable release profile through a hydrated HPMC gel layer¹². Khaled *et al.* reported 3D extrusion printing of a complex multi-compartment tablet^{12,51}. Kadry *et al.* employed HPMC and diltiazem to prepare both drug-free and drug-impregnated filaments and printed tablets with different infill densities and patterns⁴⁹. However, the shrinkage of the gel model affected the shape of the printed tablets¹³. The hot melt extrusion (HME) process is indispensable in FDM 3D printing, which allows the thermally softened filaments to be extruded by a nozzle and to be deposited layer-by-layer⁵². Genina *et al.* investigated ethylene vinyl acetate (EVA) as new feedstock material for FDM 3D printing technology to print medical drug delivery devices⁵³. Polyvinyl alcohol (PVA) is one of most widely used water-soluble synthetic polymer in various applications^{54–59}. It has been utilized as benchmark polymer⁶⁰ and drug carriers^{30,34,61,62} in 3D printed pharmaceuticals because of its good biocompatibility. Pluta *et al.* described the application of polyvinyl alcohol (PVA) in the technology of modern drug form⁶³. Goyanes *et al.* used a filament extruder to obtain filaments of PVA containing paracetamol (APAP) and fabricated PVA-based caplets with specific release profiles by FDM 3D printing⁶⁴. Tagami *et al.* produced composite tablets with a drug-loaded PVA component and a PVA or PLA filler component using FDM 3D printer with dual nozzles⁶⁵. The major shortcoming of FDM 3D printing in pharmaceutical applications is the elevated extrusion and printing temperatures required in the printing process, which limits its application in 3D printing drugs^{41,49,66,67}. So, it is not suitable to produce thermolabile drugs because the pharmaceutical excipients and active drugs may degrade at high temperature during the extrusion and printing processes^{30,51,60}. Many investigators have attempted to address this issue. Kollamaram *et al.* printed ramipril printlets by reducing the FDM printing temperature to 90 °C⁴⁸. Kempin *et al.* printed dual coated tablets by dual-extrusion-printing using three-part printing designs and utilized polycaprolactone (PCL) as the coating with a printing temperature of 58 °C⁶⁸. However, the printing process is complex and PCL is nearly insoluble. Sun *et al.* incorporated insoluble containers and light curing materials into a tablet and obtained the release profile of the drug via controlling the area of the effective component to release in accordance with the scheduled time³⁶. However, the challenge of preparing tablets with this method is the insoluble container and the complex manufacturing process. The main reason for limiting FDM 3D printing in pharmaceutical applications is that the 3D printing need to mix the drug to the polymeric filament and heat drug loading filament to a high temperature to extrude through a nozzle and deposit layer by layer.

We recently reported the fabrication of a tablet with a regular tetrahedron cavity printed by a 3D printer⁶⁹. The support structure (shell) and the drug were fabricated separately. PVA filaments were printed as a soluble container and PVA gel containing drugs was injected into the cavity at room temperature. The tablet with a regular tetrahedron cavity can only provide one kind of drug release profile, *i.e.*, increasing release profile.

The aim of this study is to explore the use of different 3D printed internal geometries as tablet formulations to obtain multiple controlled-release profiles. PVA scaffolds with different internal architecture were printed by a commercially 3D printer and injected with drug-containing gel. Tablets produced by our method have the advantages of multiple release profiles, high temperature resistance, and no residues after dissolution.

Results and Discussion

Establishment of three tablet models. Figure 1 shows three kinds of models of tablet kernels with different shapes, *i.e.*, Cylinder, Horn and Reversed Horn (R-Horn). Three types of cavities are embedded in the sphere for achieving different release profiles. In order to use more effective components and also make the drug release more uniformly, four symmetrically distributed cavities are designed and evenly placed in a sphere with a radius of 6 mm. X represents the height of cavities. Cavities will be filled with drug gel by injection. Tablets with different models will have distinct release attributes. The surface area S of the exposed drug will be constant, gradually increasing and gradually decreasing for Cylinder model, Horn model and R-Horn model, respectively. The inner architecture of the tablet would be gradually exposed with the decrease of the diameter of the tablet (Fig. S1) and the release rate would be different due to the change of surface area of medicine core.

Preparation of tablets. Figure 2 shows the tablets with Cylinder model, Horn model and R-Horn model printed by FDM 3D printing. The pale yellow part is PVA shell, and the milky white part is APAP-containing gel after drying. The weight and diameter of each tablet were measured. X , S_{top} and S_{bottom} represent the height of the cavity of each model, the surface area of top side and bottom side of each model in Fig. 1. The parameters of three kinds of tablets are listed in Table 1. Figure 3 shows the structure of pore and inner architecture of the tablet with Cylinder model before and after injection of the drug molecule.

SEM images of cross-section of 3D printed PVA shell with Cylinder model and injected APAP gel are shown in Fig. 4. The fabricated tablet is sufficiently hard and does not collapse during 3D printing. Figure 4a shows that there is no gap between PVA and APAP gel after drying. Figure 4b represents the layered structure of the shell, which is the processing feature of FDM printing. Figure 4c shows a contour line that forms the perimeter of the drug.

Figure 1. Three kinds of models of tablet kernels with different shapes. (a) The first model has four cylinder cavities placed in a sphere (Cylinder model). (b) The second model has four horn cavities placed in a sphere (Horn model). (c) The third model has four reversed horn cavities placed in a sphere (R-Horn model). The blue part represents the exposed area of the drug kernel. Along with the decrease of height, the surface area (S) will change in three kinds of models.

Figure 2. Photos of 3D printed tablets with the three models. (a) Cylinder model, (b) Horn model, (c) R-Horn model.

Model	Cavity height/mm	S_{top}/mm^2	S_{bottom}/mm^2	Weight/g	Diameter/mm
Cylinder	4.15 ± 0.14	12.57 ± 0.2	12.57 ± 0.2	0.85 ± 0.026	9.98 ± 0.18
Horn	4.48 ± 0.21	0.97 ± 0.02	17.57 ± 0.28	0.92 ± 0.019	10.20 ± 0.15
R-Horn	4.50 ± 0.24	19.27 ± 0.24	0.79 ± 0.01	0.89 ± 0.016	10.13 ± 0.12

Table 1. Parameters of the 3D printed tablets with Cylinder model, Horn model and R-Horn model.

In vitro drug release study. Tablets with Cylinder, Horn and R-Horn models are fabricated by printing PVA shell with FDM 3D printer and injecting APAP-containing gels into the cavity at room temperature. The phosphate buffer solution (PBS, pH = 6.8, 0.05 M, 900 mL) was used as representing the colonic environment⁴⁴. *In vitro* drug dissolution tests were conducted by putting the tablets in phosphate buffer solution (PBS, pH = 6.8) with stirring (50 rpm) at $37 \pm 0.5^\circ\text{C}$. The concentration of active ingredient of APAP was measured by an ultraviolet

Figure 3. The structure of the tablet with Cylinder model. (a) tablet shell with a hole, (b) tablet after injection of the drug molecule, (c) cross section of tablet shell before injection, (d) cross section of tablet shell after injection.

Figure 4. SEM visualization of cross-section of 3D printed PVA tablet with Cylinder model after injection of APAP gel. (a) Green part is the APAP gel, red part means PVA. (b) the layered structure of the shell, (c) The yellow part represents the perimeter of the drug.

Figure 5. The release profiles of APAP tablets with Cylinder model, Horn model, and R-Horn model.

spectrophotometer (UV-2601, Beijing RuiLi Analytical Instrument Co.Ltd, China). Samples were measured every 15 minutes during dissolution. The absorption peaks of APAP and PVA were detected at 243 nm and 264 nm, respectively. By the calculation, the influence of PVA could be removed, and the absorbance of the APAP could be obtained. In this way, the dissolution rate can be obtained by calculating the change of APAP concentration.

Tablets gradually melted along with the decrease of tablet diameter during dissolution. The release rate of tablets gradually varied with the change of surface area of tablets. The content of the drug was gradually exposed to PBS, which would facilitate the release rate of tablets. Tablets with three structures were dissolved according to the predetermined patterns of three models. The release was almost completed in ca. 6 hours. The release profiles of 3D printed APAP tablets are shown in Fig. 5. Tablets with three kinds of structures show constant, gradually increasing, and gradually decreasing release rate, respectively. Burst release, which is undesired for controlled-release drugs applications, is not observed from the release profiles of APAP tablets. It may be a result of using higher molecular weight PVA to decrease diffusion pathway⁶². In the previous work, we successfully printed a tablet with increasing release profile⁶⁸. In this study, tablet of each structure has its characteristic release

Figure 6. Tablets with Cylinder model during dissolution.

profile during dissolution. The Cylinder model has a constant release profile that can maintain the drug concentration within a certain range. The Horn model has an increasing release profile, which is suitable for patients with drug tolerance in the course of medication and can also be applied to hypertension which often occurs in the morning⁷⁰. The R-Horn model has a decreasing release profile that can be valuable for cases where a large dose of drug is required initially to act against their targets rapidly³⁶. The drug release data demonstrate that the internal architectures of tablets have an important effect on drug release rate.

Figure 6 reveals the dissolution of tablets with Cylinder model every 1 hour when dissolved in PBS. Over time, tablets were gradually eroded by PBS and became smaller. Although the drug became softened during dissolution, the inner architecture of scaffolds of the tablet still existed. This is because the dissolution rate of the PVA material is lower than that of the APAP gel. This phenomenon could be explained that drug release was determined by an erosion-mediated mechanism reported by a couple of studies^{13,39,44}. In terms of *in vitro* dissolution results, the release rates of the tablets with three models are positively related to the changes of surface area, which is consistent with the results reported by Goyanes⁴⁴. Generally, the release profile of single-component drugs was decreasing because the surface area of active ingredients was uncontrolled. We designed different 3D printed geometries as controlled release system to govern the inner architecture of the tablets to obtain constant, gradually increasing and gradually decreasing release profiles.

This study demonstrates that the potentials of FDM 3D printing technology to fabricate controlled release tablets with different release profiles in accordance with three kinds of models. Meanwhile, PVA can be used for different kinds of medicines, providing a positive effect for personalized medicine. Sun *et al.* used an insoluble container and light curing materials to produce a tablet for getting the drug release profile³⁶. We fabricated tablets with distinguished release profiles using PVA filaments as a soluble container filled with PVA gels containing drugs. The tablets in our work were manufactured with simple fabrication process and there is no residue after dissolution because the core and shell of tablets are soluble. In our study the drug-loaded gel was injected into the cavities without high temperature and the active ingredients of the drug were not degraded. Compared to hot melt extrusion by adding APAP into PVA filament to fabricate controlled-release drugs at about 200 °C^{32,34}, the way of injecting the drug-containing gel into the cavity at room temperature also avoids high temperature damage to the active ingredients of the tablets, and it is more suitable for the thermo-sensitive tablets. Compared to other 3D printing tablets, our work takes into account more aspects. For example, one of the typical advantages is that there is no insoluble container. Secondly, the manufacturing steps are simple so that it will be more suitable for popularizing on a large scale. Thirdly, our approach is suitable to print thermo-sensitive drugs compared to the method of adding drugs to PVA filament³². However, it still has some shortcomings such as short dissolution cycle (less than 7 hours) and lacking of the structure diversity. In the future, it is necessary to develop other gel components to fill the tablet containers so that the dissolution time would be extended.

Conclusion

We proposed a new method to fabricate customized tablets with distinguished release profiles using 3D printing technology and filling them with drug-containing gel at room temperature, which provides a new way for tailored drugs with simple fabrication process. We designed different 3D printed geometries as tablet formulations for the controlled drug release and explored the effect of inner architecture of scaffolds to obtain constant, gradually increasing or gradually decreasing release rate. The drug release rate depends on internal architectures of tablets.

Figure 7. The process of preparing tablets.

Tablets produced in this work could be dissolved evenly and there was no residue after dissolution. The manufacturing process did not degrade the active ingredients of drugs because drug-containing gels injected into the cavity at room temperature don't need to be heated high temperature of over 200 °C, which could be applied to other thermolabile tablets. In addition, the simple fabrication process for customized tablets by 3D printing technologies and easily available materials also make this general method suitable for popularization on large scale, which plays an important role in the personalized medicine.

Materials and Methods

Preparation of drug gel. Water, APAP (Anta Biotechnology, China) and PVA powder (Yingjia Inc., China) were mixed at a ratio of 6:3:1, stirred evenly for 15 minutes, then put into the vacuum chamber and evacuate until the air pressure is 400 Pa to remove bubbles of the drug gel.

3D printing PVA shell. FDM 3D printer (Creator Pro, FlashForge, China) is employed to produce a soluble container of the tablet with PVA filament (MOSHU Inc., China) at the temperature of 180 °C using a nozzle diameter of 0.3 mm at an infill rate of 100% and printing speed of 60 mm/s. It has shown that infill rate can significantly affect the release profile, and the infill rate is set to 100%, excluding the interference of infill contain cavities⁶³.

Injecting gel into PVA shell. The prepared drug gel was injected into the cavity by a 1-mL syringe with a needle (inner diameter of 0.5 mm) through a hole with a diameter of 0.7 mm, which was drilled at the thinnest part of PVA shell (Fig. 7). After injecting, the tablets were dried in a vacuum drying oven at 60 °C for 12 hours.

Scanning electron microscope (SEM) characterization. In order to investigate whether APAP adheres closely to PVA after injection or not, the cross-section images of the tablet were characterized using SEM (FEI Helios Nanolab 600i SEM, America). The cross section of the tablet was milled by sandpaper.

Ethical approval. This article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

- Xiong, Y. J. *et al.* Structural broadband absorbing metamaterial based on three-dimensional printing technology. *Acta Phys. Sin.* **67**, 084202, <https://doi.org/10.1007/s12110-009-9068-2> (2018).
- Feng, P. *et al.* A Multimaterial Scaffold With Tunable Properties: Toward Bone Tissue Repair. *Adv. Sci.* **5**, 1700817, <https://doi.org/10.1002/adv.201700817> (2018).
- Melchels, F. P. W., Feijen, J. & Grijpma, D. W. A poly(D,L-lactide) resin for the preparation of tissue engineering scaffolds by stereolithography. *Biomaterials* **30**, 3801–3809 (2009).
- Shuai, C. J. *et al.* Fabrication optimization of nanohydroxyapatite artificial bone scaffolds. *Nano* **7**, 1250015, <https://doi.org/10.1142/s1793292012500154> (2012).
- Skoog, S. A., Goering, P. L. & Narayan, R. J. Stereolithography in tissue engineering. *J Mater Sci Mater Med* **25**, 845–856 (2014).
- Galante, R., Figueiredo-Pina, C. G. & Serro, A. P. Additive manufacturing of ceramics for dental applications: A review. *Dent Mater* **35**, 825–846 (2019).
- Popov, V. K. *et al.* Laser stereolithography and supercritical fluid processing for custom-designed implant fabrication. *J Mater Sci Mater Med* **15**, 123–128 (2004).
- Huang, W., Zheng, Q., Sun, W., Xu, H. & Yang, X. Levofloxacin implants with predefined microstructure fabricated by three-dimensional printing technique. *Int J Pharm* **339**, 33–38 (2007).
- Alhnan, M. A. *et al.* Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. *Pharm Res-Dordr* **33**, 1817–1832 (2016).
- Konta, A. A., Garcia-Pina, M. & Serrano, D. R. Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful? *Bioengineering* **4**, 79 (2017).
- Goyanes, A. *et al.* 3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics. *Mol Pharmaceut* **12**, 4077–4084 (2015).
- Khaled, S. A., Burley, J. C., Alexander, M. R. & Roberts, C. J. Desktop 3D printing of controlled release pharmaceutical bilayer tablets. *Int J Pharmaceut* **461**, 105–111 (2014).

13. Skowrya, J., Pietrzak, K. & Alhnan, M. A. Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. *Eur J Pharm Sci* **68**, 11–17 (2015).
14. Huang, S., Li, C. & Xiao, Q. Yolk @ cage-Shell Hollow Mesoporous Monodispersion Nanospheres of Amorphous Calcium Phosphate for Drug Delivery with High Loading Capacity. *Nanoscale Res. Lett.* **12**, 275 (2017).
15. Jonathan, G. & Karim, A. 3D printing in pharmaceuticals: A new tool for designing customized drug delivery systems. *Int J Pharmaceut* **499**, 376–394 (2016).
16. Khan, F. A. *et al.* 3D Printing Technology in Customized Drug Delivery System: Current State of the Art, Prospective and the Challenges. *Curr Pharm Design* **24**, 5049–5061 (2018).
17. Liu, Z., Jiang, W., Nam, J., Moon, J. J. & Kim, B. Y. S. Immunomodulating Nanomedicine for Cancer Therapy. *Nano Lett.* **18**, 6655–6659 (2018).
18. Zhang, Y. *et al.* Intercalated 2D nanoclay for emerging drug delivery in cancer therapy. *Nano Res.* **10**, 2633–2643 (2017).
19. Melocchi, A. *et al.* Retentive device for intravesical drug delivery based on water-induced shape memory response of poly(vinyl alcohol): design concept and 4D printing feasibility. *Int J Pharmaceut* **559**, 299–311 (2019).
20. Liang, K., Carmone, S., Brambilla, D. & Leroux, J. C. 3D printing of a wearable personalized oral delivery device: A first-in-human study. *Sci Adv* **4**, eaat2544, [https://doi.org/ARTN eaat254410.1126/sciadv.aat2544](https://doi.org/ARTN%20eaat254410.1126/sciadv.aat2544) (2018).
21. Genina, N. *et al.* Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to *in vivo* testing. *J Control Release* **268**, 40–48 (2017).
22. Wang, J., Goyanes, A., Gaisford, S. & Basit, A. W. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. *Int J Pharmaceut* **503**, 207–212 (2016).
23. Fina, F., Goyanes, A., Gaisford, S. & Basit, A. W. Selective laser sintering (SLS) 3D printing of medicines. *Int J Pharmaceut* **529**, 285–293 (2017).
24. Fina, F. *et al.* 3D printing of drug-loaded gyroid lattices using selective laser sintering. *Int J Pharmaceut* **547**, 44–52 (2018).
25. Melocchi, A. *et al.* 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of drugs. *J Drug Deliv Sci Tec* **30**, 360–367 (2015).
26. Sadiq, M., Arifat, B., Ahmed, W., Forbes, R. T. & Alhnan, M. A. Channelled tablets: An innovative approach to accelerating drug release from 3D printed tablets. *J Control Release* **269**, 355–363 (2018).
27. Cui, M. *et al.* Exploration and Preparation of a Dose-Flexible Regulation System for Levetiracetam Tablets via Novel Semi-Solid Extrusion Three-Dimensional Printing. *J Pharm Sci* **108**, 977–986 (2019).
28. Yu, D. G. *et al.* Novel drug delivery devices for providing linear release profiles fabricated by 3DP. *Int J Pharmaceut* **370**, 160–166 (2009).
29. Katstra, W. E. *et al.* Oral dosage forms fabricated by Three Dimensional Printing (TM). *J Control Release* **66**, 1–9 (2000).
30. Goyanes, A., Buanz, A. B. M., Hatton, G. B., Gaisford, S. & Basit, A. W. 3D printing of modified-release aminosaliclylate (4-ASA and 5-ASA) tablets. *Eur J Pharm Biopharm* **89**, 157–162 (2015).
31. Fu, J. H., Yu, X. & Jin, Y. G. 3D printing of vaginal rings with personalized shapes for controlled release of progesterone. *Int J Pharmaceut* **539**, 75–82 (2018).
32. Goyanes, A. *et al.* Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. *Int J Pharmaceut* **496**, 414–420 (2015).
33. Goyanes, A. *et al.* Development of modified release 3D printed tablets (printlets) with pharmaceutical excipients using additive manufacturing. *Int J Pharmaceut* **527**, 21–30 (2017).
34. Li, Q. J. *et al.* Preparation and investigation of controlled-release glipizide novel oral device with three-dimensional printing. *Int J Pharmaceut* **525**, 5–11 (2017).
35. Siyawamwaya, M. *et al.* 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. *Eur J Pharm Biopharm* **138**, 99–110 (2019).
36. Sun, Y. J. & Soh, S. Printing Tablets with Fully Customizable Release Profiles for Personalized Medicine. *Advanced Materials* **27**, 7847–7853 (2015).
37. Trenfield, S. J., Awad, A., Goyanes, A., Gaisford, S. & Basit, A. W. 3D Printing Pharmaceuticals: Drug Development to Frontline Care. *Trends Pharmacol Sci* **39**, 440–451 (2018).
38. Trenfield, S. J. *et al.* 3D printed drug products: Non-destructive dose verification using a rapid point-and-shoot approach. *Int J Pharmaceut* **549**, 283–292 (2018).
39. Goyanes, A., Buanz, A. B. M., Basit, A. W. & Gaisford, S. Fused-filament 3D printing (3DP) for fabrication of tablets. *Int J Pharmaceut* **476**, 88–92 (2014).
40. Muwaffak, Z. *et al.* Patient-specific 3D scanned and 3D printed antimicrobial polycaprolactone wound dressings. *Int J Pharmaceut* **527**, 161–170 (2017).
41. Li, G., Peng, B., Chai, L., Wan, S. & Jiang, L. Preparation of Antibacterial Color-Coated Steel Sheets. *Int. J. Photoenergy* **2012**, 436963, <https://doi.org/10.1155/2012/436963> (2012).
42. Shu, Z., Zhang, Y., Yang, Q. & Yang, H. Halloysite Nanotubes Supported Ag and ZnO Nanoparticles with Synergistically Enhanced Antibacterial Activity. *Nanoscale Res. Lett.* **12**, 135, <https://doi.org/10.1186/s11671-017-1859-5> (2017).
43. Norman, J., Madurawe, R. D., Moore, C. M., Khan, M. A. & Khairuzzaman, A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv Drug Deliv Rev* **108**, 39–50 (2017).
44. Goyanes, A., Martinez, P. R., Buanz, A., Basit, A. W. & Gaisford, S. Effect of geometry on drug release from 3D printed tablets. *Int J Pharmaceut* **494**, 657–663 (2015).
45. Chai, X. Y. *et al.* Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone. *Sci. Rep.* **7**, 2829, [https://doi.org/ARTN 282910.1038/s41598-017-03097-x](https://doi.org/ARTN%20282910.1038/s41598-017-03097-x) (2017).
46. Solanki, N. G., Tahsin, M., Shah, A. V. & Serajuddin, A. M. Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability. *J Pharm Sci-U.S.* **107**, 390–401 (2018).
47. Palo, M., Hollander, J., Suominen, J., Yliruusi, J. & Sandler, N. 3D printed drug delivery devices: perspectives and technical challenges. *Expert Rev Med Devices* **14**, 685–696 (2017).
48. Kollamaram, G. *et al.* Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs. *Int J Pharmaceut* **545**, 144–152 (2018).
49. Kadry, H. *et al.* Multi-purposable filaments of HPMC for 3D printing of medications with tailored drug release and timed-absorption. *Int J Pharmaceut* **544**, 285–296 (2018).
50. Zhang, J. *et al.* Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: Structure and drug release correlation. *Carbohydr Polym* **177**, 49–57 (2017).
51. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J. & Roberts, C. J. 3D printing of tablets containing multiple drugs with defined release profiles. *Int J Pharmaceut* **494**, 643–650 (2015).
52. Nasereddin, J. M., Wellner, N., Alhijaj, M., Belton, P. & Qi, S. Development of a Simple Mechanical Screening Method for Predicting the Feedability of a Pharmaceutical FDM 3D Printing Filament. *Pharm Res* **35**, 151, <https://doi.org/10.1007/s11095-018-2432-3> (2018).
53. Genina, N. *et al.* Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devices. *Eur J Pharm Sci* **90**, 53–63 (2016).

54. Guo, J., Xie, D., Yang, B. & Jiang, J. Low-power logic computing realized in a single electric-double-layer MoS₂ transistor gated with polymer electrolyte. *Solid-State Electron.* **144**, 1–6 (2018).
55. Guo, J. J., Jiang, J., Zheng, Z. M. & Yang, B. C. Enhanced performance of multilayer MoS₂ transistor employing a polymer capping layer. *Org. Electron.* **40**, 75–78 (2017).
56. He, S. *et al.* Low-temperature-cured highly conductive composite of Ag nanowires & polyvinyl alcohol. *Chin. Phys. B* **26**, 078103, <https://doi.org/10.1088/1674-1056/26/7/078103> (2017).
57. Liang, Z. *et al.* Facile Synthesis of Nitrogen-Doped Microporous Carbon Spheres for High Performance Symmetric Supercapacitors. *Nanoscale Res. Lett.* **13**, 314–314 (2018).
58. Zhang, P. *et al.* Few-layered MoS₂/C with expanding d-spacing as a high-performance anode for sodium-ion batteries. *Nanoscale* **9**, 12189–12195 (2017).
59. Zhou, L., Zhou, D., Gan, W. & Zhang, Z. A ZnO/PVA/PAADDA composite electrode for rechargeable zinc-air battery. *Ionics* **23**, 3469–3477 (2017).
60. Alhijaj, M., Belton, P. & Qi, S. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing. *Eur J Pharm Biopharm* **108**, 111–125 (2016).
61. Singh, B. & Sharma, V. Design of psyllium-PVA-acrylic acid based novel hydrogels for use in antibiotic drug delivery. *Int J Pharmaceut* **389**, 94–106 (2010).
62. Rattanakit, P., Moulton, S. E., Santiago, K. S., Liawruangrath, S. & Wallace, G. G. Extrusion printed polymer structures: A facile and versatile approach to tailored drug delivery platforms. *Int J Pharmaceut* **422**, 254–263 (2012).
63. Pluta, J. & Karolewicz, B. The application of polyvinyl alcohol in the technology of modern drug form. *Polimery w medycynie* **31**, 11–17 (2001).
64. Goyanes, A., Kobayashi, M., Martinez-Pacheco, R., Gaisford, S. & Basit, A. W. Fused-filament 3D printing of drug products: Microstructure analysis and drug release characteristics of PVA-based caplets. *Int J Pharm* **514**, 290–295 (2016).
65. Tagami, T. *et al.* Defined drug release from 3D-printed composite tablets consisting of drugloaded polyvinylalcohol and a water-soluble or water-insoluble polymer filler. *Int J Pharmaceut* **543**, 361–367 (2018).
66. Awad, A., Trenfield, S. J., Gaisford, S. & Basit, A. W. 3D printed medicines: A new branch of digital healthcare. *Int J Pharm* **548**, 586–596 (2018).
67. Awad, A., Trenfield, S. J., Goyanes, A., Gaisford, S. & Basit, A. W. Reshaping drug development using 3D printing. *Drug Discov Today* **23**, 1547–1555 (2018).
68. Kempin, W. *et al.* Development of a dual extrusion printing technique for an acid- and thermo-labile drug. *Eur J Pharm Sci* **123**, 191–198 (2018).
69. Zhao, J. Z., Xu, X. W., Wang, M. N. & Wang, L. A New Model of a 3D-Printed Shell with Convex Drug Release Profile. *Dissolut Technol* **25**, 24–28 (2018).
70. Marfella, R. *et al.* Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. *Hypertension* **41**, 237–243 (2003).

Acknowledgements

The authors would like to acknowledge the support provided by National Natural Science Foundation of China (No. 21105127, No. 51673214), the Fundamental Research Funds for the Central Universities of Central South University (No.2017zzts389), and the Medical Electronics Maker Space in Central South University.

Author Contributions

X.W.X. and J.L.Y. conceived the idea. J.Z.Z. and M.N.W. carried out all the experiments as well as the data collection and analysis. L.W. contributed to data analysis. All authors discussed the results and provided comments on the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-48921-8>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019